OTCMKTS:IMNPQ Immune Pharmaceuticals (IMNPQ) Stock Price, News & Analysis $0.0010 0.00 (0.00%) As of 08/17/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Immune Pharmaceuticals Stock (OTCMKTS:IMNPQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immune Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.0001▼$0.0070VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020. Read More Receive IMNPQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNPQ Stock News HeadlinesPiper Sandler Sticks to Its Buy Rating for Immunome (IMNM)November 14, 2024 | markets.businessinsider.comDistinct immune profiles linked to adverse reactions from immunotherapyOctober 16, 2024 | msn.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.August 18 at 2:00 AM | Brownstone Research (Ad)Fact Check: Fact Check: German study did not find mRNA shots ‘eat away’ at children’s immune systemsSeptember 11, 2024 | reuters.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Robinhood, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 11, 2024 | msn.comVertex Pharmaceuticals to Buy Alpine Immune Sciences for $4.9 BillionApril 10, 2024 | money.usnews.comAlpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.April 10, 2024 | marketwatch.comVertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune dealApril 10, 2024 | msn.comSee More Headlines IMNPQ Stock Analysis - Frequently Asked Questions How have IMNPQ shares performed this year? Immune Pharmaceuticals' stock was trading at $0.0010 at the start of the year. Since then, IMNPQ shares have increased by 0.0% and is now trading at $0.0010. How do I buy shares of Immune Pharmaceuticals? Shares of IMNPQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IMNPQ CIK1208261 Webwww.immunepharma.com Phone(201) 464-2677Fax917-398-1915Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:IMNPQ) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.